STE Q4 2025: Tariffs Add $30M Headwind as Healthcare Backlog and Margin Expansion Drive 2026 Setup
STE enters 2026 with robust healthcare and AST service momentum, but $30 million in new tariffs and legal settlements will test margin resilience. Operating leverage, working capital discipline, and segmental backlog strength underpin guidance, while management signals a pragmatic approach to M&A and operational shifts in a volatile regulatory and macro environment. Investors should watch for execution on tariff mitigation and the pace of capital equipment recovery in life sciences as key levers for upside.
Summary
- Tariff Drag: $30 million in tariffs will pressure 2026 earnings, with mitigation efforts underway.
- Healthcare and AST Services Lead: Recurring revenue and backlog strength position core segments for steady growth.
- Margin Management Focus: Execution on cost savings and pricing will determine ability to offset external headwinds.
Performance Analysis
STE delivered 6% constant currency organic revenue growth in Q4, with pricing and volume gains across segments. Gross margin expanded by 170 basis points to 44.3%, as price, mix, and productivity outpaced labor inflation. EBIT margin improved to 24.8%, reflecting disciplined cost management and early restructuring benefits. Adjusted EPS grew 14% year over year, driven by both operating leverage and lower interest expense following the dental divestiture.
Segmentally, healthcare recurring revenue streams (consumables and services) outperformed on U.S. procedure volume and market share gains, while healthcare capital equipment revenue declined 5% against a tough comp. AST (Applied Sterilization Technologies) posted 9% revenue growth, with services up 7% and capital equipment shipments more than doubling, though segment margin slipped due to energy, labor, and mix headwinds. Life sciences grew 1%, with consumables offsetting capital equipment softness, but delivered a notable margin lift from mix and the CECS divestiture. Free cash flow hit a record $787 million, reflecting aggressive working capital improvements, especially inventory.
- Healthcare Margin Outperformance: Segment margin hit 25%, with volume and pricing offsetting labor inflation.
- AST Capacity Not a Limiter: Management confirmed ability to absorb higher service demand if needed.
- Backlog Sets Up 2026: Strong order book in healthcare and life sciences capital equipment supports visibility into next year.
STE’s financial positioning has improved, with net debt reduced and leverage at 1.4x EBITDA, creating optionality for capital deployment. However, the 2026 outlook embeds $30 million in tariff costs and a $40 million legal settlement, which will weigh on free cash flow and test margin resilience.
Executive Commentary
"The diversified nature of our business allowed us to deliver results in line with our original outlook, despite a few obstacles during the year... Our outperformance in consumables and services continues to be driven by procedure volumes in the U.S., as well as price and market share gains."
Dan, Chief Executive Officer
"Free cash flow for fiscal 2025 was a record $787 million, well above our full-year guidance, driven by significant working capital improvements, in particular inventory."
Mike, Chief Financial Officer
Strategic Positioning
1. Tariff Mitigation and Supply Chain Localization
STE’s $30 million tariff headwind for 2026 is split evenly between China-specific and global tariffs, with the majority of impact hitting the healthcare segment. Management emphasized that 85% of U.S. products are manufactured in North America, reducing overall exposure. Efforts to mitigate tariffs include supply chain adjustments and vendor shifts, but the full impact will be felt throughout the year, with potential for more back-end weighting as strategies evolve.
2. Recurring Revenue and Backlog Strength
Recurring revenue streams in healthcare and AST are the company’s anchor, driven by procedure volumes and market share wins in North America. The capital equipment backlog in both healthcare and life sciences offers visibility into 2026, with management citing a “great order year” and confidence in delivering on pent-up demand. This recurring revenue model, defined as predictable, contract-based or usage-driven sales, provides resilience against cyclical swings in capital equipment.
3. Margin Management and Cost Discipline
Margin expansion in 2025 was supported by pricing, mix, and productivity, while restructuring actions and working capital improvements provided additional lift. For 2026, $20 million in restructuring savings and lower litigation spend will help offset tariffs and incentive comp normalization. Management is targeting a 20 basis point EBIT margin increase at the high end of guidance, reflecting confidence in operational levers to absorb external shocks.
4. M&A and Capital Allocation Optionality
With leverage down to 1.4x EBITDA and no major M&A in recent years, STE is positioned to pursue strategic acquisitions if the right opportunities arise. Management signaled preference for greenfield expansion over acquiring aging assets, and buybacks may increase as debt ratios improve. Capital allocation will remain disciplined, balancing organic investment, M&A, and shareholder returns.
5. Industry Dynamics and Regulatory Overhang
Regulatory complexity and compliance costs, especially in sterilization and medtech, are driving industry consolidation. STE’s scale and regulatory expertise provide a competitive moat, but management remains cautious about the pace of onshoring and macro-driven shifts in manufacturing patterns. The company expects some fluidity in customer supply chain strategies, but large-scale relocation remains a slow process due to regulatory hurdles.
Key Considerations
STE’s 2026 setup is defined by margin management, tariff navigation, and the durability of recurring revenue streams. The company’s ability to execute on cost savings and backlog conversion will be critical as macro and regulatory headwinds intensify.
Key Considerations:
- Tariff Exposure Concentrated in Healthcare: Most of the $30 million tariff impact will hit the healthcare segment, with limited exposure in AST and life sciences.
- Legal Settlements to Pressure Cash Flow: A $40 million ETO legal settlement will reduce 2026 free cash flow alongside tariff costs.
- Conservative Bioprocessing Outlook: Management is cautious on bioprocessing recovery, taking a conservative stance on volume rebound in AST services.
- Strong Backlog Supports Capital Equipment Recovery: Late-year rebound and backlog in life sciences and healthcare capital equipment provide visibility into 2026 growth.
- Capital Allocation Flexibility: Reduced leverage enables opportunistic buybacks and M&A, but discipline remains paramount.
Risks
Tariffs and legal settlements present a direct hit to 2026 margins and cash flow, and mitigation efforts may not fully offset these costs. Regulatory uncertainty and macro volatility could disrupt capital equipment ordering or cause project deferrals, especially in life sciences and bioprocessing. Execution risk remains around backlog conversion and the ability to sustain pricing power in a more competitive environment.
Forward Outlook
For Q1 2026, STE guided to:
- Constant currency organic revenue growth of 6% to 7%
- EPS range of $9.90 to $10.15 for the full year, including $30 million in tariff costs
For full-year 2026, management maintained guidance:
- Revenue growth of 6% to 7% across all segments
- EBIT margin expansion of up to 20 basis points at the high end of guidance
Management highlighted several factors that will shape delivery:
- Ability to offset tariffs through supply chain and pricing actions
- Conversion of capital equipment backlog in healthcare and life sciences
Takeaways
STE’s 2026 outlook is a test of margin resilience and operational discipline as external headwinds mount.
- Tariff and Legal Headwinds: $70 million in combined tariff and legal costs will pressure cash flow and margins, requiring aggressive mitigation and cost control.
- Recurring Revenue and Backlog as Stabilizers: Durable consumables and services revenue, along with a strong capital equipment backlog, anchor the growth outlook and offer visibility despite macro uncertainty.
- Execution on Cost and Pricing: Investors should closely monitor progress on cost savings, pricing actions, and capital allocation as key levers for upside or downside surprise in 2026.
Conclusion
STE enters 2026 with solid recurring revenue momentum, improved operational leverage, and a strong capital equipment backlog, but faces material new headwinds from tariffs and legal costs. Margin management and backlog execution will be decisive in determining whether STE can deliver on its guidance and preserve its premium industry positioning.
Industry Read-Through
Tariff exposure and regulatory complexity are reshaping capital allocation and supply chain strategies across medtech and life sciences. STE’s ability to localize manufacturing and mitigate tariff impacts offers a playbook for peers, while the durability of recurring revenue streams highlights the value of services and consumables in offsetting capital equipment cyclicality. Industry consolidation is likely to accelerate as compliance costs rise, and companies with scale, operational discipline, and regulatory expertise will be best positioned to weather macro and policy shocks.